Protagonist Therapeutics Inc Stock Nasdaq
Stocks
US74366E1029
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
||
| - PTS | - |
|
| Market Cap | 7.84B 0 6.86B 6.34B 5.92B 11.14B 741B 11.39B 76.25B 29.43B 366B 29.44B 28.79B 1,269B | P/E 2026 * |
31.3x | P/E 2027 * | -101x |
|---|---|---|---|---|---|
| Enterprise Value | 7.26B 0 6.36B 5.87B 5.48B 10.32B 687B 10.56B 70.66B 27.28B 339B 27.28B 26.68B 1,176B | EV / Sales 2026 * |
14.3x | EV / Sales 2027 * | 45.5x |
| Free-Float |
97.28% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Protagonist Therapeutics Inc
| Manager | Title | Age | Since |
|---|---|---|---|
Dinesh Patel
CEO | Chief Executive Officer | 69 | 2008-11-30 |
Asif Ali
DFI | Director of Finance/CFO | 52 | 2022-04-17 |
Venkat Thalladi
CTO | Chief Tech/Sci/R&D Officer | - | 2026-03-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Dinesh Patel
BRD | Director/Board Member | 69 | 2008-11-30 |
Harold Selick
CHM | Chairman | 71 | 2014-03-18 |
William Waddill
BRD | Director/Board Member | 69 | 2016-06-30 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.94% | +8.20% | -4.77% | +1.97% | 46.2B | |
| +5.79% | +18.18% | +421.86% | +619.81% | 38.71B | |
| +1.12% | +15.21% | +22.74% | -11.83% | 31.9B | |
| +3.61% | +7.34% | +20.23% | +61.23% | 31.12B | |
| +8.02% | +5.23% | +17.67% | +35.36% | 23.77B | |
| +1.13% | +14.24% | - | - | 16.2B | |
| +1.45% | +16.19% | +72.11% | +133.41% | 15.05B | |
| -1.13% | +9.05% | +12.03% | +18.95% | 13.74B | |
| -0.60% | +8.86% | +102.74% | +97.53% | 13.42B | |
| Average | +2.19% | +10.60% | +83.08% | +119.55% | 25.57B | |
| Weighted average by Cap. | +2.59% | +10.07% | +95.90% | +140.38% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 509M 0 446M 412M 384M 724M 48.14B 740M 4.95B 1.91B 23.75B 1.91B 1.87B 82.46B | 160M 0 140M 129M 121M 227M 15.11B 232M 1.55B 600M 7.45B 600M 587M 25.87B |
| Net income | 258M 0 226M 209M 195M 367M 24.41B 375M 2.51B 969M 12.04B 969M 948M 41.81B | -87.49M -0 -76.61M -70.72M -66.04M -124M -8.27B -127M -851M -329M -4.08B -329M -321M -14.17B |
| Net Debt | -574M -0 -503M -464M -433M -816M -54.26B -834M -5.58B -2.16B -26.77B -2.16B -2.11B -92.94B | -565M -0 -494M -456M -426M -802M -53.39B -821M -5.49B -2.12B -26.34B -2.12B -2.07B -91.45B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
